首页> 外文期刊>Neurotherapeutics >Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease
【24h】

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease

机译:普利多匹定通过帕金森氏病小鼠模型中的Sigma-1受体诱导功能性神经修复

获取原文
       

摘要

Pridopidine is a small molecule in clinical development for the treatment of Huntington’s disease. It was recently found to have high binding affinity to the sigma-1 receptor, a chaperone protein involved in cellular defense mechanisms and neuroplasticity. Here, we have evaluated the neuroprotective and neurorestorative effects of pridopidine in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of parkinsonism in mice. By 5?weeks of daily administration, a low dose of pridopidine (0.3?mg/kg) had significantly improved deficits in forelimb use (cylinder test, stepping test) and abolished the ipsilateral rotational bias typical of hemiparkinsonian animals. A higher dose of pridopidine (1?mg/kg) significantly improved only the rotational bias, with a trend towards improvement in forelimb use. The behavioral recovery induced by pridopidine 0.3?mg/kg was accompanied by a significant protection of nigral dopamine cell bodies, an increased dopaminergic fiber density in the striatum, and striatal upregulation of GDNF, BDNF, and phosphorylated ERK1/2. The beneficial effects of pridopidine 0.3?mg/kg were absent in 6-OHDA-lesioned mice lacking the sigma-1 receptor. Pharmacokinetic data confirmed that the effective dose of pridopidine reached brain concentrations sufficient to bind S1R. Our results are the first to show that pridopidine promotes functional neurorestoration in the damaged nigrostriatal system acting via the sigma-1 receptor. Electronic supplementary material The online version of this article (10.1007/s13311-018-00699-9) contains supplementary material, which is available to authorized users.
机译:普利多匹定是治疗亨廷顿氏病的临床研究中的小分子。最近发现它对sigma-1受体具有高结合亲和力,sigma-1受体是一种参与细胞防御机制和神经可塑性的伴侣蛋白。在这里,我们评估了在小鼠帕金森病的单侧6-羟基多巴胺(6-OHDA)损伤模型中普利多匹定的神经保护和神经修复作用。每天给药5周后,低剂量的普利多匹定(0.3?mg / kg)可以显着改善前肢使用的不足(圆筒试验,踩踏试验),并消除了半帕金森氏症动物典型的同侧旋转偏倚。较高剂量的普利多匹定(1?mg / kg)仅能显着改善旋转偏倚,并有改善前肢使用的趋势。普利多匹定0.3?mg / kg诱导的行为恢复伴随着对黑质多巴胺细胞体的显着保护,纹状体中多巴胺能纤维密度的增加以及GDNF,BDNF和磷酸化ERK1 / 2的纹状体上调。在缺少sigma-1受体的6-OHDA损伤小鼠中,没有普利多匹定0.3?mg / kg的有益作用。药代动力学数据证实,有效剂量的普利多匹定达到足以结合S1R的大脑浓度。我们的结果首次表明,普利多匹定通过sigma-1受体在受损的黑质纹状体系统中促进功能性神经修复。电子补充材料本文的在线版本(10.1007 / s13311-018-00699-9)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号